Tiziana Life Sciences Ltd
TLSA
Company Profile
Business description
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.
Contact
2 Church Street
Clarendon House
HamiltonHM 11
BMUT: +44 207 495-2379
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
9
Stocks News & Analysis
stocks
Ask the analyst: How reliant are Guzman shares on international growth?
A year on from Guzman’s IPO, I catch up with Johannes Faul to explore what is baked into GYG’s valuation.
stocks
Nvidia: Back in business in China; Raising fair value estimate
Nvidia is poised to become more dominant than ever as it is allowed to sell its key H20 GPUs in China.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,857.70 | 41.30 | 0.47% |
| CAC 40 | 7,722.09 | 44.12 | -0.57% |
| DAX 40 | 24,009.38 | 50.91 | -0.21% |
| Dow JONES (US) | 44,254.78 | 231.49 | 0.53% |
| FTSE 100 | 8,926.55 | 11.77 | -0.13% |
| HKSE | 24,517.76 | 72.36 | -0.29% |
| NASDAQ | 20,730.49 | 52.69 | 0.25% |
| Nikkei 225 | 39,489.78 | 173.62 | -0.44% |
| NZX 50 Index | 12,880.75 | 126.16 | 0.99% |
| S&P 500 | 6,263.70 | 19.94 | 0.32% |
| S&P/ASX 200 | 8,605.20 | 43.40 | 0.51% |
| SSE Composite Index | 3,503.78 | 1.22 | -0.03% |